Although the TMPRSS2 inhibitor camostat has been reported to effectively block SARS-CoV-2 infection in cultured cells [34,70], a double-blind, randomized controlled trial with hospitalized COVID-19 patients did not find the drug’s beneficial effects in reducing time to clinical improvement, progression to severe conditions, or mortality [63]. This evidence concerns the gene TMPRSS2 and COVID-19.